| Bioactivity | JZP-MA-13 is a selective α/β-hydrolase domain 6 (ABHD6) inhibitor with an IC50 of 392 nM. JZP-MA-13 shows no inhibition of MAGL, ABHD12, FAAH, or other serine hydrolases. JZP-MA-13 is a positron emission tomography (PET) ligand for in vivo imaging of the ABHD6[1]. |
| Target | IC50: 392 nM (ABHD6) |
| Invitro | JZP-MA-13 does not bind orthosterically to CB1 or CB2 or allosterically influences canonical CB1 or CB2 signaling[1]. |
| Name | JZP-MA-13 |
| Formula | C14H15FN4O3S |
| Molar Mass | 338.36 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Karine Mardon, et al. Utilizing PET and MALDI Imaging for Discovery of a Targeted Probe for Brain Endocannabinoid α/ β-Hydrolase Domain 6 (ABHD6). J Med Chem. 2022 Dec 14. |